Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)


This company was transferred to the archive: financial data is no longer updated!

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Vertex Pharmaceuticals Inc. for $13.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Common-Size Income Statement
Quarterly Data

Vertex Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel LibreOffice Calc
3 months ended: Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Product revenues, net
Other revenues
Cost of sales
Gross profit
Research and development expenses
Sales, general and administrative expenses
Change in fair value of contingent consideration
Restructuring income (expenses)
Intangible asset impairment charge
Income (loss) from operations
Interest income
Interest expense
Other income (expense), net
Income (loss) before (provision for) benefit from income taxes
(Provision for) benefit from income taxes
Net income (loss)
(Income) loss attributable to noncontrolling interest
Net income (loss) attributable to Vertex

Based on: 10-Q (filing date: 2021-04-30), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-08-01), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-13), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-10-30), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-10-31), 10-Q (filing date: 2016-08-01), 10-Q (filing date: 2016-05-03).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Vertex Pharmaceuticals Inc.’s income (loss) from operations as a percentage of revenues increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Income (loss) before (provision for) benefit from income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Vertex Pharmaceuticals Inc.’s income (loss) before (provision for) benefit from income taxes as a percentage of revenues increased from Q3 2020 to Q4 2020 but then decreased significantly from Q4 2020 to Q1 2021.
Net income (loss) attributable to Vertex The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Vertex Pharmaceuticals Inc.’s net income (loss) attributable to Vertex as a percentage of revenues decreased from Q3 2020 to Q4 2020 but then slightly increased from Q4 2020 to Q1 2021.